Biologics/Immunotherapy News

Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Our Food Allergy: Fact vs. Fiction column and research presented at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting in San Antonio dominated our list of the most read stories in allergy and asthma for March.

Sublingual immunotherapy induced clinically significant desensitization with a favorable safety profile among children with peanut allergy, according to a study published in The Journal of Allergy and Clinical Immunology.

Patients with asthma and specific eosinophil and IgE levels experienced greater improvements in exacerbations and FEV1 with dupilumab compared with other biologics, according to a study.

Allergy immunotherapy is effective in achieving long-term results for allergic rhinitis in real-world treatment, according to a study published in The Journal of Allergy Clinical Immunology.

The extra-respiratory symptoms of aspirin-exacerbated respiratory disease improved with omalizumab at baseline and during aspirin challenges, according to a study published in The Journal of Allergy & Clinical Immunology.

SAN ANTONIO — Children on OIT who used epinephrine to treat anaphylaxis went to the ED less often than those who did not use epinephrine, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

SAN ANTONIO — Children and adolescents had high adherence rates to their and autoinjector protocols for peanut allergy, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

SAN ANTONIO — Oral immunotherapy was feasible for adults with food allergy, with specific and total IgE predicting treatment success, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

SAN ANTONIO — Patients with severe eosinophilic asthma experienced improvements in their symptoms within a week after taking benralizumab, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.